P2.03-01 Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT

Abstract

ImmunoPET is a multicentre, single arm, phase 0-1 study investigating the use of 89Zr-durvalumab PET/CT to interrogate the expression of PD-L1 in patients with NSCLC. We present the initial biodistribution data, which is being used to establish the safety and scan timepoints for a multicentre study in Stage III patients.